Rivastigmine

Names

[ Name ]:
Rivastigmine

[Synonym ]:
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
MFCD03700731
(S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenylcarbamate
Rivastigmine
N-Ethyl-N-methylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl-ester
(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
carbamic acid, ethyl(methyl)-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
3-[(1S)-1-(Dimethylamino)ethyl]phenyl ethyl(methyl)carbamate

Biological Activity

[Description]:

Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

[Related Catalog]:

Signaling Pathways >> Neuronal Signaling >> AChE

Research Areas >> Neurological Disease

[References]

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.0±0.1 g/cm3

[ Boiling Point ]:
316.2±34.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₄H₂₂N₂O₂

[ Molecular Weight ]:
250.34

[ Flash Point ]:
145.0±25.7 °C

[ PSA ]:
147.84000

[ LogP ]:
2.14

[ Vapour Pressure ]:
0.0±0.7 mmHg at 25°C

[ Index of Refraction ]:
1.518

Safety Information

[ Hazard Codes ]:
Xi

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.